All articles by RanjithKumar Dharma

RanjithKumar Dharma

Study demonstrates Xylyx Bio’s Matrikynes is safe for skin improvement

The study has proved its efficacy for anti-ageing and other topical skin applications.

Alterity Therapeutics doses first patient in Phase II MSA trial of ATH434

The effect of ATH434 treatment on neuroimaging and protein biomarkers is being assessed in the study.

ContraFect begins Phase Ib/II clinical trial of exebacase

The randomised, double-blind and placebo-controlled clinical trial is to be carried out in France.

FibroGen completes patient enrolment in pamrevlumab trial

Fibrogen enrolled 372 patients in the trial, which will assess the efficacy and safety of pamrevlumab in patients with IPF.